Trial Profile
Observer Blinded, Randomised Study to Investigate Safety, Tolerability and Long-term Immunogenicity of Different Dose Regimens and Formulations of MV-CHIK in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Chikungunya virus vaccine (Primary)
- Indications Chikungunya virus infections
- Focus Pharmacodynamics
- Sponsors Themis Bioscience
- 17 Sep 2023 Results of an analysis assessing MV-CHIK vaccination induced CHIKV-specific CD4+ and/or CD8+ T-cell responses using peripheral mononuclear blood cells (PBMC) samples from healthy adults volunteers from this trial published in the Vaccine
- 04 Feb 2020 Status changed from active, no longer recruiting to completed.
- 08 Jul 2019 Status changed from recruiting to active, no longer recruiting.